EditorThe paper entitled ‘Rosacea and demodicidosis with gain of function mutation in STAT1’ by Second et al. is of indubitable interest and prompted us to make some observations. The Authors described a patient with cutaneous and ocular rosacea that they related to demodicidosis as oral ivermectin improved the cutaneous lesions. However, the Authors did not demonstrate by skin scraping nor by standardized skin surface biopsy (SSSB) an excessive number of Demodex folliculorum (DF) mites in the pilosebaceous units to justify an oral antiparasitic treatment as a drug of first choice. DF is usually found in the pilosebaceous follicle with an average density <5 mites/cm2, whereas its density may increase in the skin affected by rosacea. The Authors used 200 μg/kg ivermectin without indicating the daily dosage nor the treatment duration. Furthermore, it is not clear if the relatives of the proband, who shared the same STAT1 mutation and were diagnosed as having rosacea, have been treated with oral ivermectin and, in such case, if they improved as well. Lastly, the Authors did not specify the disease‐free time after ivermectin, although the follow‐up is important to establish the long‐term efficacy of the treatment, considering the frequent relapses observed after traditional
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud